Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410072 · ClinicalTrials.gov registry record · Phase 3
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 669
- Enrollment target
NCT00410072 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 669 participants.
The verdict
NCT00410072, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 669 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.
Interventions
- DRUG Entecavir
- DRUG Entecavir + Tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 669 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410072
The ClinicalTrials.gov registry entry for NCT00410072 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 669 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entecavir is the first listed.
NCT00410072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410072 about?
NCT00410072 is a clinical study titled "Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B". The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.
What is the current status of trial NCT00410072?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 669 participants. The study started on 2007-04. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00410072?
The interventions under investigation include: Entecavir (DRUG), Entecavir + Tenofovir (DRUG).
Who is sponsoring clinical trial NCT00410072?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.